Reduced AKT/mTOR signaling and protein synthesis dysregulation in a Rett syndrome animal model
Authors:
- Sara RicciardiSRSara Ricciardi
- Elena M. BoggioEBElena M. Boggio
- Stefano GrossoSGStefano Grosso
- Giuseppina LonettiGLGiuseppina Lonetti
- Greta ForlaniGFGreta Forlani
- Gilda StefanelliGSGilda Stefanelli
- Eleonora CalcagnoECEleonora Calcagno
- Noemi MorelloNMNoemi Morello
- Nicoletta LandsbergerNLNicoletta Landsberger
- Stefano BiffoSBStefano Biffo
- Tommaso PizzorussoTPTommaso Pizzorusso
- Maurizio GiustettoMGMaurizio Giustetto
- 6 January 2011
- journal article
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 20 (6) , 1182-1196
Abstract
Rett syndrome (RTT) is a neurodevelopmental disorder with no efficient treatment that is caused in the majority of cases by mutations in the gene methyl-CpG binding-protein 2 (MECP2). RTT becomes manifest after a period of apparently normal development and causes growth deceleration, severe psychomotor impairment and mental retardation. Effective animal models for RTT are available and show morphofunctional abnormalities of synaptic connectivity. However, the molecular consequences of MeCP2 disruption leading to neuronal and synaptic alterations are not known. Protein synthesis regulation via the mammalian target of the rapamycin (mTOR) pathway is crucial for synaptic organization, and its disruption is involved in a number of neurodevelopmental diseases. We investigated the phosphorylation of the ribosomal protein (rp) S6, whose activation is highly dependent from mTOR activity. Immunohistochemistry showed that rpS6 phosphorylation is severely affected in neurons across the cortical areas of Mecp2 mutants and that this alteration precedes the severe symptomatic phase of the disease. Moreover, we found a severe defect of the initiation of protein synthesis in the brain of presymptomatic Mecp2 mutant that was not restricted to a specific subset of transcripts. Finally, we provide evidence for a general dysfunction of the Akt/mTOR, but not extracellular-regulated kinase, signaling associated with the disease progression in mutant brains. Our results indicate that defects in the AKT/mTOR pathway are responsible for the altered translational control in Mecp2 mutant neurons and disclosed a novel putative biomarker of the pathological process. Importantly, this study provides a novel context of therapeutic interventions that can be designed to successfully restrain or ameliorate the development of RTT.Keywords
This publication has 57 references indexed in Scilit:
- mTOR signaling: At the crossroads of plasticity, memory and diseaseTrends in Neurosciences, 2010
- ERK activation in axonal varicosities modulates presynaptic plasticity in the CA3 region of the hippocampus through synapsin IProceedings of the National Academy of Sciences, 2009
- Molecular mechanisms of mTOR-mediated translational controlNature Reviews Molecular Cell Biology, 2009
- Non–cell autonomous influence of MeCP2-deficient glia on neuronal dendritic morphologyNature Neuroscience, 2009
- Regulation of Translation Initiation in Eukaryotes: Mechanisms and Biological TargetsCell, 2009
- Rett Syndrome and the Impact of MeCP2 Associated Transcriptional Mechanisms on NeurotransmissionBiological Psychiatry, 2009
- Deletion of Mecp2 in Sim1-Expressing Neurons Reveals a Critical Role for MeCP2 in Feeding Behavior, Aggression, and the Response to StressNeuron, 2008
- Reversal of learning deficits in a Tsc2+/− mouse model of tuberous sclerosisNature Medicine, 2008
- MeCP2 Controls Excitatory Synaptic Strength by Regulating Glutamatergic Synapse NumberNeuron, 2007
- Ribosomal S6 Kinase Signaling and the Control of TranslationExperimental Cell Research, 1999